Učitavanje...
Loss of VGLL4 suppresses tumor PD‐L1 expression and immune evasion
Targeting immune checkpoints, such as PD‐L1 and its receptor PD‐1, has opened a new avenue for treating cancers. Understanding the regulatory mechanism of PD‐L1 and PD‐1 will improve the clinical response rate and efficacy of PD‐1/PD‐L1 blockade in cancer patients and the development of combinatoria...
Spremljeno u:
| Izdano u: | EMBO J |
|---|---|
| Glavni autori: | , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6589543/ https://ncbi.nlm.nih.gov/pubmed/30396996 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/embj.201899506 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|